Research advances in immune checkpoint inhibitors for triple negative breast cancer

Breast cancer has become the most common malignant tumor in the world. As a subtype of breast cancer with the worst prognosis, traditional treatment is not effective in triple negative breast cancer (TNBC). In recent years, immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of TNBC. This paper summarizes some important studies of ICIs in the treatment of TNBC in recent years, in order to explore the development and application prospect of ICIs in the treatment of TNBC.